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Association of the Haptoglobin Gene Polymorphism With Cognitive
Function and Decline in Elderly African American Adults
With Type 2 Diabetes
Findings From the Action to Control Cardiovascular Risk
in Diabetes–Memory in Diabetes (ACCORD-MIND) Study
Michal S. Beeri, PhD; Hung-Mo Lin, PhD; Mary Sano, PhD; Ramit Ravona-Springer, MD; Xiaoyu Liu, MS; Barbara B. Bendlin, PhD; Carey E. Gleason, PhD;
Elizabeth Guerrero-Berroa, PhD; Laili Soleimani, MD; Lenore J. Launer, PhD; Scott Ehrenberg; Orit Lache, MSc; Yaakov K. Seligman, BS; Andrew P. Levy, MD, PhD
Abstract
IMPORTANCE African American individuals have higher dementia risk than individuals of white
race/ethnicity. They also have higher rates of type 2 diabetes, which may contribute to this elevated
risk. This study examined the association of the following 2 classes of alleles at the haptoglobin (Hp)
locus that are associated with poor cognition, cardiovascular disease, and mortality: Hp 1-1
(associated with poor cognition and cerebrovascular disease) and Hp 2-1 and Hp 2-2 (associated with
greater risk of myocardial infarction and mortality). An additional polymorphism in the promoter
region of the Hp 2 allele, restricted to individuals of African descent, yields a fourth genotype, Hp
2-1m. African American adults have a higher prevalence of Hp 1-1 (approximately 30%) compared
with individuals of white race/ethnicity (approximately 14%), but the potential role of the Hp
genotype in cognition among elderly African American individuals with type 2 diabetes is unknown.
OBJECTIVE To assess the association of the Hp genotypes with cognitive function and decline in
elderly African American adults with type 2 diabetes.
DESIGN, SETTING, AND PARTICIPANTS This cohort study used publicly available data and
specimens from the Action to Control Cardiovascular Risk in Diabetes–Memory in Diabetes
(ACCORD-MIND) study to investigate the association of the Hp genotypes with cognitive function
and decline in 466 elderly African American participants with type 2 diabetes. The hypothesis was
that the Hp 1-1 genotype compared with the other genotypes would be associated with more
cognitive impairment and faster cognitive decline in elderly African American adults with type 2
diabetes. The initial ACCORD trial was performed from October 28, 1999, to September 15, 2014. This
was a multicenter clinical study performed in an academic setting.
EXPOSURES The Hp genotypes were determined from serum samples by polyacrylamide gel
electrophoresis and by enzyme-linked immunosorbent assay.
MAIN OUTCOMES AND MEASURES The Mini-Mental State Examination (MMSE) was used to
measure cognitive function and change after 40 months. The MMSE score ranges from 0 to 30
points; higher scores represent better cognition. Associations were examined with analysis of
covariance and linear regression, adjusting for age, sex, education, baseline glycated hemoglobin
level, systolic blood pressure, diastolic blood pressure, cholesterol level, creatinine level, and
(continued)
Key Points
Question Is the haptoglobin genotype
associated with cognition in African
American adults with type 2 diabetes?
Findings In this cohort study of 466
African American adults with type 2
diabetes, haptoglobin 1-1 carriers had
the poorest cognitive function, while
haptoglobin 2-1m carriers had the
highest cognitive function. Older
haptoglobin 1-1 carriers had greater
cognitive decline over time compared
with the other genotypes.
Meaning The haptoglobin gene
polymorphism may contribute to
cognitive impairment in African
American adults who have type 2
diabetes.
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Abstract (continued)
treatment arm (intensive vs standard). The cognitive change model adjusted also for the baseline
MMSE score.
RESULTS Among 466 African American study participants (mean [SD] age, 62.3 [5.7] years), 64.8%
were women, and the genotype prevalences were 29.4% (n = 137) for Hp 1-1, 36.1% (n = 168) for Hp
2-1, 10.9% (n = 51) for Hp 2-1m, and 23.6% (n = 110) for Hp 2-2. The groups differed in their baseline
MMSE scores (P = .006): Hp 1-1 had the lowest MMSE score (mean [SE], 25.68 [0.23]), and Hp 2-1m
had the highest MMSE score (mean [SE], 27.15 [0.36]). Using the least squares method, the
40-month decline was significant for Hp 1-1 (mean [SE], −0.41 [0.19]; P = .04) and for Hp 2-2 (mean
[SE], −0.68 [0.21]; P = .001). However, the overall comparison across the 4 groups did not reach
statistical significance for the fully adjusted model. The interaction of age with the Hp 1-1 genotype on
MMSE score decline estimate per year change was significant (mean [SE], −0.87 [0.37]; P = .005),
whereas it was not significant for Hp 2-1 (mean [SE], 0.06 [0.37]; P = .85), Hp 2-1m (mean [SE], −0.06
[0.51]; P = .89), and Hp 2-2 (mean [SE], −0.44 [0.41]; P = .29), indicating that cognitive decline in Hp
1-1 carriers was accentuated in older ages, whereas it was not significant for the other Hp genotypes.
CONCLUSIONS AND RELEVANCE In this study, the Hp 1-1 genotype, which is 2-fold (approximately
30%) more prevalent among African American individuals than among individuals of white race/
ethnicity, was associated with poorer cognitive function and greater cognitive decline than the other
Hp genotypes. The Hp gene polymorphism may explain the elevated dementia risk in African
American adults. The neuropathological substrates and mechanisms for these associations merit
further investigation.
JAMA Network Open. 2018;1(7):e184458. doi:10.1001/jamanetworkopen.2018.4458
Introduction
African American adults have a significantly higher risk of developing dementia and Alzheimer
disease than other racial/ethnic groups,1-3 even after adjusting for age, sex, and education.1 In
addition to nongenetic factors, such as poor nutrition4 and obesity,5 higher rates of cerebrovascular
disease and cardiovascular risk factors6 (especially type 2 diabetes7) in African American adults
suggest that the genetics of vascular disease may underlie this increased risk of dementia.
Haptoglobin (Hp) is a hemoglobin-binding protein synthesized in the liver and the brain. Two
classes of alleles at the Hp locus yield 3 genotypes, Hp 1-1, Hp 2-1, and Hp 2-2. An additional
polymorphism in the promoter region of the Hp 2 allele, restricted to individuals of African descent,
yields a fourth genotype, Hp 2-1m.8,9 The biophysical properties of the Hp polymers formed in these
4 Hp genotypes are distinct, but little is known about the Hp 2-1m biology. The associations of Hp
with health—studied almost solely in individuals of white race/ethnicity—are primarily in patients with
type 2 diabetes.10 Hp 2-2 is associated with increased risk of myocardial infarction and mortality.11,12
Hp 1-1 has been linked to cerebral small vessel disease (eg, lacunar infarcts and white matter
lesions).13-16 Consistent with the latter, it has been shown in a cohort of elderly white patients with
type 2 diabetes that Hp 1-1 carriers have poorer cognitive function compared with Hp 2-1 and Hp 2-2
carriers.17 A study18 examining the prevalence of the Hp genotypes across different populations
reported that African American adults have a higher prevalence of Hp 1-1 (approximately 30%)
compared with individuals of white race/ethnicity (approximately 14%), but the potential role of the
Hp genotype in poorer cognition and cognitive decline in elderly African American adults with type
2 diabetes has not been studied.
We took advantage of publicly available data and specimens from the Action to Control
Cardiovascular Risk in Diabetes–Memory in Diabetes (ACCORD-MIND) study to investigate the
association of the Hp genotypes with cognitive function and decline in 466 elderly African American
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participants. We hypothesized that the Hp 1-1 genotype compared with the other genotypes would
be associated with more cognitive impairment and faster cognitive decline in elderly African
American adults with type 2 diabetes.
Methods
ACCORD Study Design
The rationale, design, eligibility criteria, and glycemia intervention of the initial ACCORD trial have
been reported previously.19 The ACCORD trial was performed from October 28, 1999, to September
15, 2014. Briefly, this was a multicenter clinical study in an academic setting that recruited volunteers
with type 2 diabetes and a glycated hemoglobin level of 7.5% or more who were between the ages
of 40 and 79 years and had cardiovascular disease. All 10 251 patients were randomly assigned to
receive comprehensive intensive therapy targeting a glycated hemoglobin level of less than 6.0% or
to receive standard therapy targeting a glycated hemoglobin level of 7.0% to 7.9%. The study
protocol was approved by the institutional review boards of its 77 participating sites, as well as a
review panel at the National Heart, Lung, and Blood Institute. All patients provided written informed
consent. This study followed Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) reporting guideline for cohort studies.
As a substudy, the ACCORD-MIND study20 aimed to examine the association of intensive vs
standard glycemic control with cognitive function and decline. In total, 2977 ACCORD trial
participants were included in this substudy, 466 of whom were African American individuals who had
complete baseline information on the Mini-Mental State Examination (MMSE) score and relevant
covariates. Cognition was measured at baseline and at the 20-month and 40-month visits.
Hp Genotyping
Through a request for data and serum samples to the Biologic Specimen and Data Repository
Information Coordinating Center (BIOLINCC) system of the National Heart, Lung, and Blood
Institute,21 specimens were sent to the Technion–Israel Institute of Technology (Haifa) and were
genotyped for Hp by polyacrylamide gel electrophoresis (PAGE)22 and by enzyme-linked
immunosorbent assay (ELISA),23 with no knowledge of any participant-related information. The
ELISA assay provides a spectrophotometric readout that has been validated as having greater than
99% accuracy for Hp 1-1, Hp 2-1, and Hp 2-2.23,24 However, to our knowledge, the present study is
first in using the ELISA assay for assessing Hp 2-1m, whose reading was (as expected) intermediate
between Hp 1-1 and Hp 2-1. The PAGE method uses hemoglobin enrichment of serum22 and provides
a signature banding pattern for Hp 1-1, Hp 2-1, Hp 2-1m, and Hp 2-2 (Figure 1). Hp 2-1m is found only
in African American individuals and notably was not seen in any of the samples analyzed from
individuals of white race/ethnicity (eg, the Israel Diabetes and Cognitive Decline study25), consistent
with previous studies among white individuals26 and nonwhite individuals,27,28 and testifies to the
accuracy of the Hp typing.23,24
Hp Protein Quantitation
To investigate the potential role of Hp protein levels on cognition and in the association of the Hp
genotype with cognition, we quantified Hp protein levels. A 96-well microtiter dish (96-Well
Microtiter Microplates; Nunc) was coated with 100 μL of rabbit anti-Hp in phosphate-buffered saline
(PBS) (antibody titer 1:3000; Dako) and incubated overnight. The wells were rinsed with wash buffer
(PBS with 0.05% TWEEN 20) and then incubated with blocking buffer (PBS with 5% bovine serum
albumin and 0.05% TWEEN 20) for 2 hours at room temperature. The wells were then rinsed with
wash buffer; serum samples diluted 1:100 000 or Hp standards (0.1-1.0 ng) in blocking buffer were
added, and the plate was incubated overnight. The next day, the wells were washed, and mouse
anti-Hp (1:10 000; Sigma) was added in blocking buffer for 1 hour. Thereafter, the wells were washed,
and horseradish peroxidase anti-mouse antibody (1:20 000; Jackson ImmunoResearch
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Laboratories) in blocking buffer was added for 30 minutes. The wells were washed again, and
substrate was added for 20 minutes, followed by stop solution (1N sulfuric acid). The plate was read
at 450 nm in an ELISA reader.
Hp Standards
To evaluate the role of Hp protein levels in cognition and in the association of the Hp genotypes with
cognition, Hp protein was obtained by immunoaffinity purification on an anti-Hp column. The Hp
protein levels of the standards were determined using the following extinction coefficients (for
solutions of 1 mg/mL), in ascending order: 1.18 for Hp 2-2, 1.21 for Hp 2-1, 1.23 for Hp 2-1m, and 1.24 for
Hp 1-1.
Mini-Mental State Examination
The MMSE29 is a global cognitive screening instrument that assesses orientation, memory, attention/
concentration, language, and visual construction. The MMSE score ranges from 0 to 30 points;
higher scores represent better cognition.
Statistical Analysis
Descriptive data are reported as number (percentage) or mean (SD), as appropriate. Unadjusted
bivariate analyses included 1-way analysis of variance or χ2 test, as appropriate, to compare Hp
genotype differences relative to sociodemographic and clinical variables. The sociodemographic
variables included baseline age, sex, and education (high school or less, some college or technical
school, high school graduate or general equivalency diploma, and college graduate or more). The
clinical variables included baseline glycated hemoglobin level, systolic blood pressure, diastolic blood
pressure, cholesterol level, creatinine level, and cardiovascular disease (which includes stroke and
myocardial infarction). An indicator variable for treatment arm (intensive vs standard) was also
included.
Figure 1. Determination of Haptoglobin (Hp) Genotype by Nondenaturing Polyacrylamide Gel Electrophoresis
Lane
1 2 3 4 5
Demonstration of the 4 possible Hp genotypes by
polyacrylamide gel electrophoresis. Each of the 4 Hp
genotypes has a signature banding pattern resulting
from differences in stoichiometry of the polymeric
composition of the different Hp genotypes.13 In lane 1,
Hp 1-1 has a single band corresponding to the Hp 1-1
dimer (see the arrowhead pointing to the right). In lane
5, Hp 2-1m has a band present in Hp 1-1 and 2 additional
bands corresponding to Hp 2-1 polymers (trimer and
quatermer [see the arrowheads pointing to the left]).
In lanes 2 and 4, Hp 2-1 has the bands present in Hp 2-1,
as well as higher-order Hp 2-1 polymers. In lane 3, Hp
2-2 has only Hp 2-2 trimers or higher-order Hp 2-2
polymers.
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The primary analysis used the MMSE to assess the association of the Hp genotypes with MMSE
score and measure cognitive function and change after 40 months. eTable 1 in the Supplement lists
the distribution of the MMSE scores in the 4 genotypes. Two sets of linear regression models were fit.
The primary model adjusted for baseline age, sex, and education. In a second model, we further
adjusted for baseline clinical factors (glycated hemoglobin level, systolic blood pressure, diastolic
blood pressure, cholesterol level, creatinine level, and cardiovascular disease) and the glycemic
control study arm.
The association between Hp genotypes and MMSE score was examined both cross-sectionally
and longitudinally using the same primary and secondary sets of adjustment models as described in
the previous paragraph. The cross-sectional analyses compared the MMSE score differences
measured at baseline across the 4 Hp genotypes, while the longitudinal analysis using the mixed
model with random participants focused on the change in MMSE score from baseline to the
20-month and 40-month follow-ups, with additional adjustment for the baseline MMSE score and
use of blood pressure and oral glycemic control medications at the time of follow-up visits. For the
change models, we assumed that missing data and dropouts were at random (ie, the unobserved
data could be anticipated using the covariates considered in the model through the expectation-
maximization algorithm).
The ACCORD-MIND study participants were young (mean age, 62 years) in the context of a
study on cognitive decline, while the MMSE shows greater variability in older individuals.30
Therefore, we performed secondary analyses to examine the interaction of age with Hp genotypes
on the MMSE score change. We hypothesized that, at older ages, there would be greater cognitive
decline in those with the Hp 1-1 genotype. To investigate this, we first plotted the MMSE score change
against the baseline age by genotype using nonparametric local linear regression (locally weighted
smoothing 80% smoothed with 95% CI). We then repeated the aforementioned longitudinal models
(in the previous paragraph) but allowed each genotype to have its specific age association (ie,
replacing the baseline age variable with the interaction term of baseline age with each individual
genotype). Statistical analysis was performed using a software program (SAS, version 9.4; SAS
Institute Inc). Two-sided P < .05 was defined as the significance level in all statistical tests.
Results
Table 1 lists the sociodemographic and clinical characteristics of the participants by Hp genotype.
Among 466 African American study participants (mean [SD] age, 62.3 [5.7] years), 64.8% were
Table 1. Baseline Characteristics of the Sample and by the Hp Genotype
Variable Overall Hp 1-1 Hp 2-1 Hp 2-1m Hp 2-2 P Value
Baseline, No. (%)a 466 (100) 137 (29.4) 168 (36.1) 51 (10.9) 110 (23.6) NA
40-mo Follow-up, No. (%)a 409 (100) 120 (29.3) 146 (35.7) 46 (11.2) 97 (23.7) NA
Age, mean (SD), y 62.3 (5.7) 61.7 (5.6) 62.6 (5.7) 63.7 (6.4) 61.8 (5.3) .10
Female, No. (%)b 302 (64.8) 94 (68.6) 113 (67.3) 33 (64.7) 62 (56.4) .19
High school or less, No. (%)b 236 (50.6) 62 (45.3) 93 (55.4) 29 (56.9) 52 (47.3) .22
Glycated hemoglobin level, mean (SD), % 8.6 (1.2) 8.6 (1.2) 8.5 (1.1) 8.2 (0.9) 8.8 (1.2) .007
SBP, mean (SD), mm Hg 139.2 (18.5) 138.8 (18.1) 138.2 (18.5) 142.3 (18.1) 139.9 (19.3) .54
DBP, mean (SD), mm Hg 77.3 (10.8) 77.7 (11.4) 76.7 (10.4) 76.5 (10.5) 78.1 (11.1) .70
Cholesterol level, mean (SD), mg/dL 184.5 (39.6) 184.5 (38.4) 184.5 (39.5) 180.9 (37.9) 186.3 (42.3) .89
Creatinine level, mean (SD), mg/dL 0.93 (0.23) 0.93 (0.24) 0.92 (0.23) 0.93 (0.22) 0.93 (0.21) .89
Cardiovascular disease, No. (%)b 96 (20.6) 23 (16.8) 39 (23.2) 13 (25.5) 21 (19.1) .42
Abbreviations: DBP, diastolic blood pressure; Hp, haptoglobin; NA, not applicable; SBP,
systolic blood pressure.
SI conversion factors: To convert glycated hemoglobin level to proportion of total
hemoglobin, multiply by 0.01; to convert cholesterol level to millimoles per liter, multiply
by 0.0259; and to convert creatinine level to micromoles per liter, multiply by 88.4.
a Denominators are values in the Overall column.
b Denominators are values in the Baseline row.
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women, and the genotype prevalences were 29.4% (n = 137) for Hp 1-1, 36.1% (n = 168) for Hp 2-1,
10.9% (n = 51) for Hp 2-1m, and 23.6% (n = 110) for Hp 2-2. The Hp groups differed in baseline
glycated hemoglobin levels, with the highest level for the Hp 2-2 genotype (8.8%) and the lowest
level for the Hp 2-1m genotype (8.2%). Otherwise, there were no significant differences among the
4 groups.
Hp Genotype and Baseline MMSE Scores
In the overall analysis of covariance controlling for the sociodemographic variables, the groups
differed in their baseline MMSE scores (Table 2): Hp 1-1 had the lowest MMSE score (mean [SE],
25.68 [0.23]) and Hp 2-1m had the highest MMSE score (mean [SE], 27.15 [0.36]). Post hoc
comparisons among pairs of the Hp genotypes (eTable 2 in the Supplement), adjusting for multiple
comparisons, demonstrated that those with the Hp 2-1m genotype had better scores than those with
the Hp 1-1 genotype (mean [SE] difference, 1.46 [0.30]); P = .001) and those with the Hp 2-2
genotype (mean [SE] difference, 1.18 [0.44]; P = .04). In model 2, the comparison of Hp 1-1 with Hp
2-1m withstood adjustment for multiple comparisons (mean [SE] difference, 1.39 [0.30]; P = .007).
All other comparisons of pairs of genotypes showed no differences in the baseline MMSE scores.
Hp Genotype and Longitudinal MMSE Score
Table 3 summarizes model 1 and model 2 for longitudinal decline in MMSE score by Hp genotype. The
MMSE score declined over time among those with the Hp 1-1, Hp 2-1, and Hp 2-2 genotypes; in the
Hp 2-1m group, there was marginal improvement. Using the least squares method, the 40-month
decline was significant for Hp 1-1 (mean [SE], −0.41 [0.19]; P = .04) and for Hp 2-2 (mean [SE], −0.68
Table 2. Baseline MMSE Scores by Hp Genotype Using the
Least Squares Methoda
Variable
MMSE Score, Mean (SE)
Model 1 Model 2
Hp 1-1 25.68 (0.23) 25.74 (0.23)
Hp 2-1 26.26 (0.21) 26.21 (0.21)
Hp 2-1m 27.15 (0.36) 27.13 (0.37)
Hp 2-2 25.97 (0.25) 26.02 (0.25)
P value .006 .01
Abbreviations: Hp, haptoglobin; Mini-Mental State Examination, MMSE.
a Model 1 controls for age, sex, and education. Model 2 controls for age, sex,
education, baseline glycated hemoglobin level, systolic blood pressure,
diastolic blood pressure, cholesterol level, creatinine level, history of
cardiovascular disease at baseline, and glycemic control study arm.
Table 3. Decline in MMSE Score Over 40 Months by Hp Genotype Using the Least Squares Methoda
Variable
Model 1 Model 2
MMSE Score, Mean (SE) P Value MMSE Score, Mean (SE) P Value
Hp 1-1 −0.39 (0.19) .04 −0.41 (0.19) .04
Hp 2-1 −0.26 (0.17) .13 −0.22 (0.18) .21
Hp 2-1m 0.16 (0.30) .59 0.16 (0.31) .60
Hp 2-2 −0.67 (0.21) .001 −0.68 (0.21) .001
P valueb NA .14 NA .13
Abbreviations: Hp, haptoglobin; Mini-Mental State Examination, MMSE; NA, not applicable.
a Model 1 controls for the baseline MMSE score, age, sex, and education. Model 2 controls for the baseline MMSE score,
age, sex, education, baseline glycated hemoglobin level, systolic blood pressure, diastolic blood pressure, cholesterol
level, creatinine level, history of cardiovascular disease at baseline, glycemic control study arm, use of blood pressure
medication at the visit, and use of oral glycemic control medication at the visit.
b P value for comparisons among the 4 genotype groups sliced by visit.
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[0.21]; P = .001). However, the overall comparison across the 4 groups did not reach statistical
significance for model 1 or the fully adjusted model 2 (Table 3 and eFigure 1 in the Supplement).
The Role of Age in the Association of Hp With Cognitive Decline
As shown in Figure 2, the MMSE score change was subtle for all Hp genotypes in the younger ages
(eFigure 2 in the Supplement shows the age distribution of the cohort). The line became significantly
steeper for the Hp 1-1 genotype near age 70 years, indicating more decline in older Hp 1-1 carriers.
However, in the older age strata, the lines for the other 3 genotypes remained flat. This observation
was confirmed by the parametric regression models. The interaction of age with the Hp 1-1 genotype
on MMSE score decline estimate per year change was significant (mean [SE], −0.87 [0.37]; P = .005),
whereas it was not significant for Hp 2-1 (mean [SE], 0.06 [0.37]; P = .85), Hp 2-1m (mean [SE], −0.06
[0.51]; P = .89), and Hp 2-2 (mean [SE], −0.44 [0.41]; P = .29).
Hp Protein Levels
To explore whether the levels of the protein product of the Hp gene are associated with cognition
and cognitive decline and whether they link the Hp genotypes to cognition, we repeated all analyses
first using the serum level of Hp protein as the predictor and then including it as a covariate. The Hp
protein level was not associated with cognition or cognitive decline, and its inclusion as a covariate in
the Hp genotype and cognition models did not alter the results.
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Discussion
In this cohort study of elderly African American adults having long-standing type 2 diabetes and
participating in the ACCORD-MIND study, we found suggestive evidence that the Hp 1-1 genotype
was associated with poorer global cognitive function and with significant cognitive decline at the
40-month follow-up, adjusting for age, sex, and education as well as when also adjusting for
cardiovascular risk factors and the glycemic control study arm. In addition, among Hp 1-1 carriers,
older baseline age may modulate the extent of the decline. The Hp protein level was not associated
with cognition and did not alter the Hp genotype and cognition associations, suggesting that the
structure and function of the Hp genotypes differentially influence cognition. Our study also
confirms a 2-fold (approximately 30%) higher prevalence of the Hp 1-1 genotype among African
American adults, as shown in another study,18 compared with individuals of white race/ethnicity
(approximately 14%).25 The study by Langlois and Delanghe18 focused on African American adults
from the Seattle, Washington, area, and the present study broadens to numerous regions in the
United States.
Although the data suggest that individuals with different Hp genotypes had some difference in
the amount of cognitive decline, the main association of Hp genotype with cognitive decline was not
statistically significant. However, there was a significant interaction between age and Hp genotype
such that older Hp 1-1 carriers showed significantly greater MMSE score decline over time compared
with the other genotypes. Poorer cognitive outcomes in Hp 1-1 genotype carriers may be caused by
greater cerebrovascular disease. The Hp 1-1 genotype has been shown to correlate with stroke14 and
with white matter hyperintensities13 in adults with type 1 diabetes. Similarly, in middle-aged patients
with hypertension, the Hp 1-1 genotype correlates with the extent of deep white matter damage,15
and the frequency of the Hp 1 allele was significantly higher in patients with first symptomatic lacunar
stroke due to small vessel disease.31 The cluster numbers of endothelial cells, which mitigate cerebral
small vessel disease, are lower when Hp 1-1 protein is added to progenitor cell cultures32; cluster
formation is poorer in patients with lacunar stroke with the Hp 1-1 phenotype.32 In contrast, the Hp 2
allele potentiates gene expression of proangiogenic factors in endothelial progenitor cells, potentially
improving blood perfusion and recovery from ischemic injury.33,34 The association of the Hp 1-1
genotype with cerebrovascular disease and poor cognitive outcomes and the association of the Hp
2-2 genotype with peripheral vascular complications of type 2 diabetes suggest that Hp may serve
different functions depending on the neuropathological processes in vascular diseases of different
organs. This association merits further investigation because it may have significant clinical
implications, suggesting caution against the universal application of therapies targeting vascular
disease across all Hp genotypes.
The Hp 2-1m genotype, pertaining solely to individuals of African descent and investigated
herein for the first time (to our knowledge) in the context of cognitive aging, was associated with
better cognitive function at baseline despite being the group with the oldest age and lowest
education. Longitudinally, it was the only group with a suggestion of cognitive improvement over
time. Because these results may suggest neuroprotection of this genotype, further investigation is
warranted.
Strengths and Limitations
Strengths of the study include the large sample of African American adults with longitudinal cognitive
data and a well-validated diagnosis of type 2 diabetes. The generalizability of the results may be
limited because the ACCORD-MIND study sample is derived from a clinical trial and includes
participants with severe type 2 diabetes, thus not representing the population of aging individuals
with type 2 diabetes. Therefore, the study may have a survivor bias. For example, the Hp 2-2
genotype is associated with greater risk of myocardial infarction.11 Because there were no differences
herein in the prevalence of myocardial infarction among different genotypes, it is possible that the
Hp 2-2 individuals in the ACCORD-MIND study may be those who survived a myocardial infarction.
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The distribution of the Hp genotypes was similar in those with complete (n = 409) and incomplete
data (n = 57) data, suggesting that, in this short-term study, censorship does not depend on Hp
genotype. It has recently been shown in older persons of white race/ethnicity with type 2 diabetes
that poor glycemic control was strongly associated with hippocampal volume among those with the
Hp 1-1 genotype but not among other genotypes.35 This outcome suggests that individuals with the
Hp 1-1 genotype may be more vulnerable to the deleterious influences of poor glycemic control.
Conclusions
To our knowledge, this is the first study to investigate the role of the Hp genotype in cognitive
function and decline among elderly African American adults with type 2 diabetes, who are at
particularly high risk of developing dementia1-3 and other type 2 diabetes complications.6,7 We show
that the Hp 1-1 genotype, which is 2-fold (approximately 30%) more prevalent among African
American adults than among individuals of white race/ethnicity, was associated with poorer cognitive
function and greater cognitive decline than the other Hp genotypes. The Hp gene polymorphism may
explain the elevated dementia risk in African American adults. Future research directions should
address the neurobiological substrates and mechanisms underlying the associations of Hp and
cognition in a more representative sample of older African American adults with type 2 diabetes and
with a broader and more sensitive cognitive assessment.
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